oral
immunotherapi
oit
consid
promis
approach
food
allergi
fa
howev
current
oit
strategi
limit
term
longterm
efficaci
safeti
previous
demonstr
kakkonto
tradit
japanes
herbal
medicin
suppress
occurr
allerg
symptom
murin
model
ovalbumin
ova
induc
fa
attribut
induct
regulatori
cell
studi
establish
oit
model
use
fa
mice
alreadi
establish
allerg
symptom
determin
whether
kakkonto
could
improv
efficaci
oit
oit
method
consist
initi
administr
small
amount
ova
slowli
increas
amount
allerg
symptom
decreas
oittreat
fa
mice
oit
significantli
downregul
immun
responserel
gene
express
fa
mous
colon
decreas
level
mous
mast
cell
marker
mast
cell
degranul
fa
mous
plasma
moreov
concomit
use
kakkonto
significantli
enhanc
effect
oit
allerg
symptom
combin
therapi
suppress
immun
respons
mast
cell
degranul
addit
oit
significantli
increas
popul
regulatori
cell
fa
mous
colon
popul
increas
oit
combin
kakkonto
furthermor
combin
therapi
kakkonto
reduc
express
radegrad
enzym
mrna
fa
mous
colon
find
indic
combin
oit
kakkonto
repres
promis
approach
fa
treatment
kakkonto
tradit
japanes
herbal
medicin
kampo
medicin
approv
ethic
drug
ministri
health
labour
welfar
japan
mhlwj
qualiti
enhanc
oit
efficaci
kakkonto
murin
fa
model
plo
one
fig
outlin
experiment
design
ovasensit
balbc
mice
challeng
time
per
week
oral
administr
nonheat
ova
solut
day
mice
treat
kakkonto
oit
oitkakkonto
placebo
mc
methylcellulos
solut
steril
water
daili
day
one
hour
oral
heat
ova
challeng
kakkonto
placebo
mc
oral
administr
oit
mice
receiv
nonheat
ova
challeng
assess
allerg
symptom
day
day
respect
food
allergi
fa
repres
increasingli
preval
human
health
problem
affect
larg
proport
gener
popul
develop
countri
children
adult
selfreport
allergi
least
food
despit
increas
preval
fa
therapeut
option
remain
limit
treatment
proven
acceler
develop
oral
toler
provid
effect
protect
accident
exposur
current
standard
manag
reli
antigen
avoid
emerg
prepared
allergenspecif
oral
immunotherapi
oit
consid
promis
potenti
therapeut
approach
fa
induc
perman
immunolog
toler
food
allergen
report
success
sever
clinic
trial
oit
milk
egg
peanut
clinicaltri
gov
identifi
clinic
trial
describ
tabl
howev
date
avail
evid
effect
riskbenefit
ratio
potenti
longterm
consequ
oit
insuffici
support
use
clinic
practic
addit
optim
dose
length
therapi
also
unclear
previou
studi
oit
use
varieti
dose
strategi
heterogen
make
comparison
among
difficult
moreov
underli
molecular
cellular
mechan
oit
remain
unclear
understand
precis
mechan
oit
determin
whether
oit
effect
safe
treatment
fa
appropri
anim
model
need
establish
howev
appropri
anim
model
oit
egg
allergi
avail
kakkonto
tradit
japanes
herbal
medicin
commonli
use
japan
import
aspect
contribut
frequent
use
kakkonto
kakkonto
highli
effect
safe
medicin
treatment
common
cold
influenza
allerg
rhiniti
diarrhea
either
sole
sourc
therapi
combin
modern
western
medicin
previous
demonstr
kakkonto
suppress
occurr
allerg
symptom
murin
fa
model
kakkonto
induc
regulatori
cell
treg
colon
novel
mechan
underli
therapeut
action
report
allergenspecif
immunotherapi
increas
product
local
system
treg
essenti
step
patient
experiment
model
therefor
hypothes
kakkonto
might
potenti
therapeut
drug
treatment
immun
diseas
induc
disrupt
intestin
mucos
toler
fa
studi
demonstr
concomit
use
kakkonto
oit
oitkakkonto
result
better
therapeut
efficaci
oit
use
oit
mous
model
establish
studi
fourweekold
male
balbc
mice
purchas
japan
slc
inc
shizuoka
japan
mice
purchas
tacon
laboratori
germantown
ny
usa
mice
hous
experiment
anim
facil
univers
toyama
studi
approv
anim
experi
committe
univers
toyama
author
accord
guid
care
use
laboratori
anim
univers
toyama
accredit
ministri
educ
cultur
sport
scienc
technolog
japan
mice
kept
spf
condit
observ
approxim
everi
day
adequaci
food
water
bed
gener
overal
health
condit
especi
monitor
condit
stool
consist
approv
stipul
protocol
effort
made
minim
suffer
discomfort
anim
quantiti
ingredi
kakkonto
standard
mhlwj
kakkonto
product
code
lot
number
use
present
studi
purchas
tsumura
tokyo
japan
kakkonto
compos
seven
dri
medicin
herb
pueraria
radix
cinnamomi
cortex
zizyphi
fructu
paeonia
radix
ephedra
herba
zingiberi
rhizoma
glycyrrhiza
radix
accord
manufactur
inform
seven
medic
herb
extract
hot
water
extract
solut
separ
insolubl
wast
concentr
remov
water
reduc
pressur
spraydri
use
produc
dri
extract
powder
chemic
pattern
extract
obtain
threedimension
hplc
analysi
shown
fig
main
bioactiv
compound
kakkonto
puerarin
isoflavonoid
deriv
pueraria
radix
possess
mani
pharmacolog
effect
antiinflamm
vasodil
neuroprotect
antioxid
anticanc
experiment
protocol
murin
food
allergi
model
induct
fa
perform
previous
describ
briefli
mice
sensit
twice
interv
ovalbumin
ova
albumin
chicken
egg
white
grade
v
sigmaaldrich
st
loui
mo
usa
presenc
mg
aluminum
hydroxid
thermo
scientif
rockford
il
usa
adjuv
intraperiton
inject
two
week
system
prime
mice
repeatedli
given
mg
ova
crude
ovalbumin
powder
nacalai
tesqu
kyoto
japan
dissolv
water
intragastr
feed
needl
three
time
per
week
diarrhea
assess
visual
monitor
mice
h
follow
intragastr
challeng
outlin
fig
experiment
oit
treatment
fa
model
mice
perform
oral
administr
increas
dose
mgday
ova
grade
v
sigmaaldrich
day
day
ova
dissolv
steril
water
heat
boil
water
bath
min
heat
ova
administr
mgday
day
mgday
day
mgday
day
mgday
day
mgday
day
mgday
day
mgday
day
mgday
day
kakkonto
mgkg
suspend
methylcellulos
solut
administr
h
oral
heat
ova
challeng
combin
therapi
mice
challeng
mg
ova
nonheat
evalu
clinic
symptom
beforeaft
oit
treatment
symptom
allerg
diarrhea
assess
h
nonheat
ova
challeng
sever
classifi
follow
normal
stool
soft
stool
loos
stool
mild
diarrhea
sever
diarrhea
fluid
stool
mice
show
profus
liquid
stool
mild
diarrhea
sever
diarrhea
fluid
stool
record
diarrhea
one
hour
postoit
nonheat
ova
challeng
mice
sacrif
cervic
disloc
cm
proxim
colon
excis
proxim
colon
flush
icecold
salin
frozen
liquid
nitrogen
total
rna
extract
proxim
colon
sepasol
super
nacalai
tesqu
accord
manufactur
instruct
revers
transcript
perform
use
exscript
rt
reagent
kit
takara
bio
shiga
japan
random
primer
follow
realtim
pcr
realtim
pcr
amplif
cytochrom
famili
subfamili
b
polypeptid
cellular
retino
acid
bind
protein
aldehyd
dehydrogenas
famili
subfamili
dehydrogenas
gapdh
perform
use
sybr
premix
ex
taq
takara
bio
primer
sequenc
primer
shown
tabl
realtim
pcr
perform
use
takara
takara
bio
pcr
reaction
condit
sec
follow
cycl
sec
sec
target
mrna
normal
gapdh
mrna
intern
control
sampl
result
express
ratio
rel
fa
group
averag
data
repres
experi
repeat
three
time
one
hour
postoit
nonheat
ova
challeng
plasma
sampl
collect
anesthesia
minim
anim
suffer
distress
mous
mast
cell
proteas
level
plasma
assay
marker
mast
cell
degranul
use
elisa
kit
purchas
ebiosci
san
diego
ca
usa
ovaspecif
ige
level
plasma
measur
elisa
method
refer
briefli
microtit
plate
coat
ova
grade
v
sigmaaldrich
overnight
plasma
sampl
incub
h
bind
ovaspecif
ige
detect
use
biotinyl
rat
antimous
ige
yamasa
tokyo
japan
avidinhrp
ebiosci
bind
ovaspecif
detect
use
hrpconjug
sheep
antimous
southern
biotech
birmingham
al
usa
endpoint
titer
ovaspecif
immunoglobulin
antibodi
express
reciproc
last
dilut
show
level
absorb
background
level
absorb
peak
nm
total
rna
extract
proxim
colon
mrna
purifi
mixtur
total
rna
use
rneasi
mini
kit
qiagen
crawley
uk
mrna
mice
group
mix
microarray
analysi
perform
describ
previous
use
genechip
mous
gene
st
array
affymetrix
santa
clara
ca
usa
genechip
scan
genechip
scanner
affymetrix
gene
express
analyz
use
genechip
analysi
suit
softwar
affymetrix
transcript
level
mediancent
indic
color
code
blue
low
red
high
data
analyz
use
genespr
silicon
genet
redwood
citi
ca
usa
ingenu
pathway
analysi
ipa
ingenu
system
redwood
citi
ca
usa
http
wwwingenuitycom
extract
signific
gene
determin
gene
ontolog
identifi
canon
pathway
associ
differenti
express
gene
signific
associ
microarray
data
canon
pathway
calcul
use
fisher
exact
test
immunohistochem
stain
perform
accord
procedur
describ
previou
report
briefli
one
hour
postoit
nonheat
ova
challeng
proxim
colon
excis
fix
immers
paraformaldehyd
embed
oct
compound
cut
section
expos
antiserum
marker
mous
mucos
mast
cell
moredun
scientif
scotland
uk
incub
sheep
antidonkey
igg
jackson
immunoresearch
laboratori
immunostain
section
examin
use
fluoresc
microscop
system
olympu
tokyo
japan
filter
set
olympu
photograph
use
olympu
digit
camera
olympu
histolog
stain
quantit
analyz
use
imagej
softwar
one
hour
postoit
nonheat
ova
challeng
colon
excis
flush
icecold
salin
lamina
propria
lp
cell
isol
colon
previous
describ
brief
colon
dissect
short
segment
stir
rpmi
contain
fetal
bovin
serum
fb
mm
edta
min
lp
cell
isol
enzymat
dissoci
procedur
use
collagenas
wako
osaka
japan
discontinu
percol
densitygradi
centrifug
perform
purifi
lp
cell
singl
cell
suspens
mesenter
lymph
node
mln
prepar
pass
mesh
filter
peripher
blood
lymphocyt
pbl
isol
densiti
centrifug
pancol
densiti
gml
pan
biotech
aidenbach
germani
splenic
dendrit
cell
spdc
naiv
cell
spt
cell
isol
spleen
wildtyp
balbc
mice
mice
respect
spleen
digest
collagenas
wako
minut
singlecel
suspens
obtain
forc
cell
strainer
bd
bioscienc
franklin
lake
nj
usa
cell
isol
purifi
use
mous
lymphocyt
enrich
setdm
bd
bioscienc
mous
dendrit
cell
enrich
setdm
bd
bioscienc
accord
manufactur
instruct
carboxyfluorescein
diacet
succinimidyl
ester
cfse
label
spt
cell
x
spdc
x
cocultur
complet
rpmi
medium
fb
equitechbio
kerrvil
tx
usa
ethanol
gibco
grand
island
ny
usa
unitml
penidcillin
invitrogen
eggenstein
germani
streptmysin
invitrogen
glutamin
invitrogen
ngml
peprotech
rocki
hill
nj
usa
ngml
recombin
human
peprotech
ngml
anti
thermo
scientif
ngml
anti
thermo
scientif
ova
peptid
hokkaido
system
scienc
hokkaido
japan
retino
acid
ra
nm
day
well
flatbottom
plate
prolifer
naiv
cell
assay
cfse
dilut
cell
stain
describ
flow
cytometri
analysi
cfse
dilut
assay
analysi
cell
popul
among
gate
cell
perform
flow
cytometri
analyz
cell
surfac
marker
flow
cytometri
lp
cell
stain
min
peconjug
antimous
clone
bd
bioscienc
stain
intracellular
perform
accord
manufactur
instruct
use
stain
buffer
set
ebiosci
apcconjug
antimouserat
clone
ebiosci
cell
wash
pb
bovin
serum
albumin
bsa
permeabil
h
fixationpermeabil
work
solut
ebiosci
cell
preincub
mous
fcr
block
reagent
milteni
biotec
auburn
ca
usa
min
stain
prevent
antibodi
bind
fc
receptor
stain
isotyp
control
antibodi
perform
experi
discrimin
posit
stain
cell
base
data
obtain
isotyp
control
antibodi
flow
cytometri
analysi
perform
use
fac
canto
ii
bd
bioscienc
valu
express
mean
se
respect
test
control
group
fa
group
statist
signific
evalu
use
either
mannwhitney
test
bonferroni
dunn
posthoc
test
multipl
comparison
probabl
valu
p
consid
statist
signific
estim
therapeut
effect
oit
mice
alreadi
establish
allerg
symptom
determin
clinic
util
kakkonto
combin
therapi
oit
balbc
mice
sensit
challeng
nonheat
ova
mice
develop
signific
allerg
diarrhea
increas
ovaspecif
ige
oit
treatment
perform
oral
administr
increas
dose
heat
ova
allerg
symptom
respons
oit
eg
allerg
diarrhea
observ
oit
significantli
suppress
occurr
sever
allerg
diarrhea
mice
establish
fa
compar
oit
combin
therapi
oit
kakkonto
oitkakkonto
amelior
allerg
symptom
treatment
kakkonto
alon
inhibit
allerg
diarrhea
fig
occurr
diarrhea
day
untreat
fa
mice
oit
mice
oitkakkonto
mice
respect
signific
differ
p
result
show
oitkakkonto
significantli
enhanc
therapeut
effect
oit
occurr
sever
allerg
diarrhea
p
elucid
mechan
underli
therapeut
effect
oit
oitkakkonto
examin
gene
express
proxim
colon
transcriptom
analysi
indic
predomin
immun
respons
mast
cell
activ
untreat
fa
mice
howev
select
gene
express
associ
immun
respons
cell
surfac
marker
transcript
factor
secret
factor
decreas
oit
mice
oitkakkonto
downregul
gene
express
fig
furthermor
decreas
mrna
express
verifi
realtim
rtpcr
fig
contrast
oit
oitkakkonto
effect
increas
level
ovaspecif
plasma
ige
fa
mice
fig
plasma
level
decreas
oit
significantli
decreas
oit
kakkonto
fig
furthermor
transcriptom
analysi
proxim
colon
show
mast
cell
degranulationrel
gene
express
reduc
oit
mice
oit
kakkonto
diminish
gene
express
fig
assess
mucos
mast
cell
infiltr
proxim
colon
unexpectedli
number
posit
cell
significantli
increas
follow
oit
oitkakkonto
fig
result
support
mrna
express
data
proxim
colon
fig
flow
cytometri
analysi
show
oit
significantli
increas
popul
treg
lp
mln
pbl
popul
markedli
significantli
increas
oitkakkonto
fig
obtain
insight
underli
mechan
oitkakkontoinduc
increas
treg
lp
perform
bioinformat
analysi
microarray
data
set
use
pathway
network
analysi
system
ipa
cluster
biolog
process
correspond
gene
differenti
express
oitkakkonto
shown
involv
larg
extent
canon
pathway
biosynthesi
degrad
ra
fig
ra
enhanc
convers
naiv
cell
treg
thu
focus
analys
primarili
upon
set
gene
previou
associ
retinoid
biosynthesi
measur
mrna
express
level
regul
ra
metabol
use
realtim
pcr
mrna
express
main
radegrad
enzym
rabind
protein
significantli
downregul
oitkakkonto
wherea
differ
observ
mrna
express
capabl
activ
ra
precursor
activ
ra
metabolit
fig
address
involv
ra
naiv
cell
differenti
ra
ad
cocultur
spdc
cfselabel
naiv
spt
cell
shown
fig
ra
significantli
elev
proport
treg
dosedepend
manner
effect
oit
fa
demonstr
human
patient
howev
current
therapeut
efficaci
oit
satisfactori
underli
mechan
elucid
recent
valid
variou
antigen
administr
rout
includ
sublingu
rout
subcutan
rout
epicutan
rout
eye
anterior
chamber
rout
immun
toler
induct
shown
experiment
clinic
addit
ampl
evid
indic
peripher
mucos
immun
system
interact
common
mucos
immun
system
therefor
suggest
administr
rout
immun
toler
induct
effect
treatment
food
allergi
fact
report
oit
epicutan
immunotherapi
epit
promis
treatment
food
allergi
howev
date
oit
effect
induc
toler
epit
efficaci
epit
enough
treatment
food
allergi
addit
oit
util
pathway
oral
toler
physiolog
immun
respons
ingest
food
antigen
therefor
select
oit
studi
present
studi
combin
oit
kakkonto
result
much
better
inhibitori
effect
ovaspecif
allerg
immun
respons
mous
intestin
compar
effect
either
oit
alon
kakkonto
alon
henc
demonstr
oit
effect
treat
allerg
diarrhea
fa
mice
kakkonto
markedli
enhanc
therapeut
effect
oit
previou
studi
reveal
intestin
mucos
immun
particip
develop
fa
previou
result
indic
allerg
symptom
result
enhanc
intestin
immun
respons
fa
model
addit
oit
mice
significantli
display
downregul
immun
responserel
gene
express
compar
fa
mice
oitkakkonto
downregul
gene
express
taken
togeth
find
indic
suppress
effect
oit
oitkakkonto
attribut
diminish
immun
respons
rapid
desensit
mast
cell
allergen
propos
mechan
underli
allergenspecif
immunotherapi
variou
experiment
model
number
mechan
thought
involv
render
mast
cell
unrespons
allergen
even
presenc
allergenspecif
ige
elucid
involv
mast
cell
mediat
effect
oit
oitkakkonto
measur
plasma
level
marker
mast
cell
degranul
observ
plasma
tend
differenti
naiv
cell
mice
cocultur
spdc
presenc
ova
peptid
ra
nm
nm
nm
nm
nm
vehicl
n
p
vs
vehicl
enhanc
oit
efficaci
kakkonto
murin
fa
model
decreas
oit
mice
significantli
decreas
oitkakkonto
mice
chang
close
correl
allerg
symptom
immun
responserel
gene
express
previou
report
show
treatment
pentagalloylglulcos
constitu
kakkonto
significantli
inhibit
degranul
mucos
mast
cell
vitro
studi
suppress
fa
vivo
murin
model
attribut
downregul
surfac
express
mucos
mast
cell
observ
current
data
rais
possibl
kakkonto
significantli
enhanc
therapeut
abil
oit
suppress
degranul
mucos
mast
cell
oit
mice
increas
proport
treg
found
patient
treat
immunotherapi
addit
induct
treg
murin
model
postul
essenti
step
allergenspecif
immunotherapi
maazi
et
al
demonstr
effect
allergenspecif
immunotherapi
partial
explain
treg
deplet
treg
partial
abrog
suppress
effect
induc
therapi
furthermor
hadi
et
al
demonstr
oral
ova
administr
induc
local
expans
antigenspecif
treg
lp
neither
mln
peripher
lymph
node
use
otii
cell
adopt
transfer
mous
model
antigenspecif
treg
lp
contribut
induct
immun
toler
therefor
studi
elucid
immunomodul
effect
oit
oitkakkonto
assess
proport
treg
lp
follow
treatment
inde
model
found
increas
proport
treg
follow
oit
similar
report
employ
differ
model
allerg
diseas
notabl
increas
markedli
enhanc
oitkakkonto
number
recent
report
demonstr
ra
activ
metabolit
vitamin
enhanc
differenti
naiv
cell
treg
vitro
vivo
addit
oral
administr
vitamin
subcutan
administr
ra
result
increas
number
treg
lp
indic
ra
posit
regulatori
factor
gener
treg
intestin
studi
show
radepend
differenti
treg
cocultur
dc
naiv
cell
concentr
ra
cell
tissu
regul
ra
metabol
cytochrom
enzym
primarili
respons
ra
degrad
therefor
suppress
enzym
increas
endogen
ra
concentr
enhanc
differenti
treg
furthermor
bind
ra
transfer
present
ra
degrad
studi
oitkakkonto
significantli
downregul
mrna
express
suggest
oitkakkonto
may
increas
ra
concentr
therebi
induc
treg
lp
colon
granulocytemacrophag
colonystimul
factor
gmcsf
major
role
inflammatori
autoimmun
reaction
report
enhanc
gmcsf
product
associ
exacerb
atop
dermat
rhiniti
contrast
gmcsf
shown
suppress
experiment
autoimmun
diseas
mice
induc
natur
treg
find
rais
possibl
gmcsf
addit
synergist
effect
oit
kakkonto
oitkakkonto
addit
studi
need
clearli
defin
mechan
pathway
gmcsf
act
antiinflammatoryregulatori
cytokin
inflammatori
cytokin
treg
respons
allergen
associ
suppress
effector
cell
allerg
symptom
mast
cell
basophil
eosinophil
cell
essenti
requir
tcell
cytokin
prime
surviv
activ
cell
suppress
activ
treg
fa
mice
treat
oit
oitkakkonto
effici
provid
tcell
cytokin
addit
direct
tregmast
cell
contact
treg
limit
degranul
mast
cell
convers
report
signal
blockad
mast
cell
induc
function
treg
promot
toler
induct
prevent
food
allergen
sensit
murin
peanut
fa
model
furthermor
adopt
transfer
studi
show
infus
treg
result
decreas
serum
level
fa
model
indic
constitut
treg
suffici
modul
effer
phase
allerg
reaction
mediat
mast
cell
base
observ
treg
mice
treat
oit
oitkakkonto
inactiv
mucos
mast
cell
play
pivot
role
pathogenesi
fa
variou
mechan
therebi
induc
toler
food
antigen
suppress
fa
taken
togeth
result
current
studi
demonstr
kakkonto
enforc
therapeut
effect
oit
thu
allevi
allerg
symptom
murin
fa
model
indic
combin
therapi
might
use
therapeut
intervent
undertaken
enhanc
tregmedi
immun
respons
suppress
immun
respons
final
inactiv
mast
cell
activ
thu
find
could
import
implic
therapeut
use
combin
therapi
oit
kakkonto
treatment
fa
